What is semiconductor wafer cleaning and why is it critical in chip manufacturing?

Silicon wafers must be cleaned hundreds of times during semiconductor manufacturing — between virtually every processing step. Why cleaning is critical: contamination kills yield — a single particle or chemical residue can create defects that render a chip non-functional; modern chips have features at 3-7nm (billionths of a meter) scale where even microscopic contamination causes failures; chemical residue removal — etching, deposition, and polishing steps leave chemical residues that must be completely removed before the next step; oxide removal — native silicon oxide forms immediately on silicon surfaces; it must be removed to create clean interfaces for transistor formation. Traditional wafer cleaning uses batch processing — many wafers simultaneously in chemical baths. ACM's single-wafer cleaning processes one wafer at a time: SAPS uses megasonic waves in alternating phase patterns to remove particles without damaging delicate surface structures; TEBO creates precisely timed micro-bubbles that collapse to scrub surfaces. Single-wafer cleaning provides superior uniformity and control versus batch methods, making it increasingly essential for advanced nodes where wafer-to-wafer consistency is critical.

What are U.S. export controls on semiconductor equipment and how do they affect ACM Research?

The U.S. government regulates exports of semiconductor manufacturing equipment for national security reasons — advanced chip-making equipment is considered a strategic technology that could enhance foreign military capabilities. The Bureau of Industry and Security (BIS) within the Commerce Department issues Export Administration Regulations (EAR) specifying which equipment requires an export license to sell to specific countries or companies. Major export control actions affecting semiconductor equipment: October 2022 — Biden administration imposed comprehensive restrictions on selling advanced semiconductor equipment to Chinese companies; restrictions covered equipment for advanced nodes (below approximately 16nm logic); ACM's advanced cleaning equipment may require export licenses for certain Chinese customers. The Netherlands and Japan later joined U.S. export controls (ASML, Tokyo Electron, Nikon affected). Impact on ACM: ACMR has sought to comply with export controls while continuing sales to Chinese customers in permitted categories (mature node, not cutting-edge chip production); continued tightening of export controls is an existential risk to ACMR's China-concentrated business model; ACM is attempting to diversify internationally (South Korea, Taiwan) to reduce dependence on China.

What is China's semiconductor self-sufficiency strategy and why is it driving equipment demand?

China's Semiconductor Self-Sufficiency Strategy (sometimes called 'Made in China 2025' in semiconductors) is a national initiative to reduce dependence on U.S. and allied country semiconductor technology by building domestic chip design and manufacturing capability. Key drivers of Chinese semiconductor equipment demand: U.S. export controls — U.S. restrictions on selling advanced chips (Nvidia GPUs, Intel Xeon) and chip-making equipment to China incentivize Chinese companies to build domestic alternatives; government funding — China's 'Big Fund' (National Integrated Circuit Industry Investment Fund) has invested $60B+ in domestic semiconductor companies (SMIC, CXMT, YMTC, Hua Hong Semiconductor); major end markets — Huawei's smartphone and 5G network chip needs, data center AI chip requirements, and consumer electronics drove demand for domestic chips. Chinese chipmakers SMIC (foundry), CXMT (DRAM), YMTC (NAND flash), and others are investing tens of billions in new fabs, creating massive demand for semiconductor equipment of all types. ACM Research benefits because Chinese chipmakers actively prefer Chinese-developed equipment suppliers to reduce dependence on foreign technology — ACM's Chinese-American leadership and dual listing in both Shanghai and U.S. markets positions it uniquely to serve this domestic preference.

brimindinvest.com / compare / pgny-vs-acmrLIVE

PGNY

Progyny, Inc. · Healthcare - Benefits Management

$26.08

+6.02% this month

VERSUS

⟷

COMPARE

ACMR

ACM Research, Inc. · Technology - Semiconductor Equipment

$109.87

+65.34% this month

Scoreboard verdict

Across AI score, momentum, valuation, upside, operating margin

PGNY

2

ACMR

2

MIXED SETUP

Comparison scoreboard

MIXED SETUP

AI Score

PGNY 29.9

ACMR ✓56.4

1Y Return

PGNY +20.46%

ACMR ✓+336.17%

Fwd P/E

PGNY ✓11.82

ACMR 48.76

Target Up.

PGNY ✓+13.98%

ACMR -19.33%

Op. Margin

PGNY N/A

ACMR N/A

Metrics last refreshed: 6/20/2026

Quick take

PGNY vs ACMR Stock Comparison: AI Score, Valuation, Performance and Upside

PGNY (Progyny) and ACMR (ACM Research) are growth companies in completely different sectors — Progyny provides fertility benefits management to enterprise employers in a category it largely created, while ACM Research sells semiconductor wafer cleaning equipment primarily to Chinese chipmakers. Both face specific risks in their respective markets: Progyny from employer budget pressure and healthcare competition; ACMR from U.S.-China semiconductor trade restrictions and China revenue concentration.

PGNY vs ACMR is specialty fertility benefits management with enterprise employer customer flywheel (Progyny's IVF and reproductive health benefit administration serving large tech companies with measurable ROI from high-quality clinic network) versus differentiated semiconductor wafer cleaning equipment serving China's domestic chip build-out (ACM Research's SAPS and TEBO cleaning technology serving Chinese chipmakers' massive investment in domestic semiconductor manufacturing with U.S. export control headwinds) — healthcare benefits growth versus semiconductor equipment with geopolitical risk.

Live analysis · updated 6/20/2026

PGNY and ACMR are closely matched — they split the tracked metrics evenly. ACMR has delivered stronger 1-year price return (+336.17% vs +20.46%), though PGNY trades at the lower forward P/E (11.82x vs 48.76x). Analyst consensus implies meaningfully more upside for PGNY (+13.98%) than for ACMR (-19.33%).

Normalized 1Y performance

PGNY

ACMR

Recent returns

PGNY

ACMR

Analyst price targets & sentiment

PGNY · 11 analysts

STRONG BUYHOLDSTRONG SELL

Strong Buy (1.4/5.0)

Price target range

analyst low$26.00
analyst high$31.00
analyst mean$29.73
current price$26.08

+14.0% upside to analyst mean

ACMR · 7 analysts

STRONG BUYHOLDSTRONG SELL

Strong Buy (1.5/5.0)

Price target range

analyst low$70.00
analyst high$125.00
analyst mean$88.63
current price$109.87

-19.3% upside to analyst mean

Who should consider this stock?

PGNY may suit investors who:

→Want exposure to the growing employer fertility benefits market — Progyny created the smart fertility benefits category and has built the strongest enterprise client roster, creating a competitive moat from customer references and network effects
→Value Progyny's demographic tailwinds (delayed family formation, increasing IVF prevalence) as structural long-term demand drivers independent of economic cycle
→Prefer Progyny's U.S.-centric, less geopolitically exposed business model versus ACM Research's China concentration with significant U.S. export control risk

ACMR may suit investors who:

→Believe China's domestic semiconductor investment will continue growing despite U.S.-China trade tensions, creating sustained demand for ACM's differentiated cleaning equipment from domestic Chinese chipmakers
→Value ACM's technical differentiation in single-wafer cleaning for advanced semiconductor nodes as a genuine technological moat that even larger equipment companies have not fully replicated
→Accept the geopolitical risk of ACM's China concentration as compensated by the rapid growth of China's semiconductor equipment spending as the country pursues chip self-sufficiency

Performance & AI score

Metric	PGNY	ACMR
AI score	29.9	56.4
AI rank	#2307	#236
Latest close	$26.08	$109.87
1M return	+6.02%	+65.34%
6M return	+0.35%	+194.08%
1Y return	+20.46%	+336.17%

$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

Period	PGNY	ACMR
1Y ago	$12.05K (+20.5%) started 2025-06-18	$43.62K (+336.2%) started 2025-06-18
5Y ago	$4.05K (-59.5%) started 2021-06-18	$32.39K (+223.9%) started 2021-06-18
10Y ago	$16.36K (+63.6%) started 2019-10-25	$588.59K (+5785.9%) started 2017-11-02

Hypothetical — past performance does not guarantee future results.

Valuation & upside potential

Metric	PGNY	ACMR
Market cap	$2.04B	$7.59B
Trailing P/E	33.87	83.87
Forward P/E	11.82	48.76
Price/Sales	1.58	7.91
EV/Revenue	1.46	5.84
Analyst target	$29.73	$88.63
Target upside	+13.98%	-19.33%

Growth, profitability & risk

Metric	PGNY	ACMR
Revenue growth	1.40%	34.20%
Earnings growth	70.60%	-18.70%
EPS growth	+70.60%	-18.70%
FCF margin	+15.48%	-14.83%
Operating margin	N/A	N/A
Profit margin	5.24%	9.48%
ROIC proxy	14.94%	7.60%
Return on equity	14.94%	7.60%
Dividend yield	0.00%	0.00%
Beta	1.04	1.98
Debt/equity	6.21	16.18
Current ratio	2.13	3.51
Quick ratio	2.07	2.48

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

PGNY max drawdown42.65%

ACMR max drawdown46.34%

PGNY max wkly drop20.81%

ACMR max wkly drop26.17%

5Y risk snapshot

PGNY max drawdown79.49%

ACMR max drawdown84.81%

PGNY max wkly drop31.87%

ACMR max wkly drop41.14%

10Y risk snapshot

PGNY max drawdown79.49%

ACMR max drawdown87.23%

PGNY max wkly drop31.87%

ACMR max wkly drop41.14%

Performance metrics by period

Period	Metric	PGNY	ACMR
1Y	Growth	+20.46%	+336.17%
	CAGR	+20.48%	+336.61%
	Sharpe ratio	0.53	2.22
	Max drawdown	42.65%	46.34%
	Max daily drop	20.49%	19.95%
	Max wkly drop	20.81%	26.17%
5Y	Growth	-59.55%	+223.94%
	CAGR	-16.56%	+26.50%
	Sharpe ratio	-0.12	0.64
	Max drawdown	79.49%	84.81%
	Max daily drop	32.65%	26.50%
	Max wkly drop	31.87%	41.14%
10Y	Growth	+63.61%	+5785.89%
	CAGR	+7.69%	+60.40%
	Sharpe ratio	0.35	0.93
	Max drawdown	79.49%	87.23%
	Max daily drop	32.65%	28.18%
	Max wkly drop	31.87%	41.14%

Business comparison

Category	PGNY	ACMR
Company	Progyny, Inc.	ACM Research, Inc.
Sector	Healthcare - Benefits Management	Technology - Semiconductor Equipment
Industry	N/A	N/A
Core business	Progyny is a specialty benefits management company for fertility and family-building benefits — it administers IVF (in vitro fertilization), egg freezing, gestational carrier arrangements, and adoption assistance as employer-sponsored benefits. Progyny works with large employers (Salesforce, Google, Meta, Microsoft, and hundreds of other enterprise customers) to offer their employees comprehensive fertility benefits rather than the limited, often ineffective fertility coverage in standard health insurance plans. Progyny manages a network of 900+ fertility clinics and physicians.	ACM Research develops and sells semiconductor wafer cleaning equipment — critical process tools used by chipmakers to clean silicon wafers between manufacturing steps. ACM's flagship technology is SAPS (Space Alternating Phase Shift) and TEBO (Timely Energized Bubble Oscillation) — single-wafer cleaning technologies that provide superior cleaning of advanced semiconductor devices versus batch cleaning methods used by legacy equipment. ACM Research operates primarily in China (ACMR) but also in Korea and the U.S., and has a separate public vehicle (ACM Research Shanghai) for its China operations.
Investor focus	Investors track Progyny's covered lives under management (number of employees with access to Progyny benefits), revenue per covered life, client retention and additions (enterprise employers adding Progyny), utilization rates, and Progyny's expansion into pharmacy benefits and adjacent fertility services.	Investors track ACM's revenue growth from China semiconductor manufacturers, the U.S. export controls impact on ACM's China business, international market expansion (Korea, Southeast Asia) to diversify beyond China, and new product development beyond cleaning into electroplating and other process steps.

PGNY strengths

→First-mover in smart fertility benefits management with strong enterprise customer roster — Progyny created the employer fertility benefits management category and has signed the most prestigious enterprise employers; strong customer references make it easier to add new clients
→Fertility benefits drive measurable ROI for employers — IVF success rates through Progyny's high-quality clinic network are significantly better than random fertility care; fewer failed IVF cycles means lower total treatment costs for employers; Progyny can demonstrate cost-per-successful-live-birth metrics that justify the benefit cost
→Demographic tailwind from employees delaying family formation — increasingly, employees in professional roles delay having children; fertility challenges are more common with advancing age; employer-sponsored fertility benefits become more valuable as demographic trends continue

ACMR strengths

→Differentiated single-wafer cleaning technology serving advanced semiconductor needs — SAPS and TEBO cleaning achieve superior particle removal and chemical compatibility for advanced nodes (3nm, 5nm) where traditional batch cleaning methods leave residues that cause chip defects
→China domestic semiconductor investment creating strong local demand — China's semiconductor self-sufficiency push has dramatically increased domestic chipmaker capex; ACM's established presence with CXMT, SMIC, YMTC, and other Chinese fabs creates a growing revenue base from China's chip buildout
→Expanding product portfolio beyond cleaning — ACM has developed electroplating (copper interconnect) and furnace (thermal processing) tools, expanding its addressable market within the fab tool budget beyond single-wafer cleaning

Risks to watch — PGNY

→Employer benefit budget pressure in economic downturns could slow new client additions — fertility benefits are discretionary (employers can choose not to offer them); economic downturns that force benefit cuts could reduce new Progyny client additions
→Competition from health insurer and pharmacy benefit manager expansion into fertility — Aetna, UnitedHealth, Cigna, and CVS/Caremark have expanded their fertility benefit offerings; if insurers build competitive fertility management capabilities, Progyny's differentiation may be challenged
→Concentration risk in tech sector employer clients — Progyny's client base skews toward large technology companies; if the tech sector cuts benefits broadly (as occurred with tech layoffs in 2022-2023), Progyny's revenue growth could be impacted

Risks to watch — ACMR

→U.S. export control risks on China semiconductor equipment — U.S. export controls on semiconductor equipment sold to Chinese chipmakers are an existential risk for ACM's China-concentrated business; further tightening of controls could restrict ACM's ability to sell to leading-edge Chinese fabs
→China revenue concentration — approximately 90%+ of ACM's revenue comes from China; any disruption to China's semiconductor industry investment (economic slowdown, escalating U.S.-China tensions, government policy changes) would severely impact ACMR
→ACM Research Shanghai dual-listed structure creates complexity — ACM's China operations are separately publicly traded in Shanghai (ACM Research Shanghai), creating complex accounting, corporate governance, and shareholder alignment questions for U.S. investors in ACMR

Frequently asked questions

In vitro fertilization (IVF) is an assisted reproductive technology where: eggs are retrieved from the ovaries after hormonal stimulation; eggs are fertilized with sperm in a laboratory; resulting embryos are cultured for 3-5 days; and one or more embryos are transferred to the uterus. A single IVF cycle in the U.S. costs approximately $12,000-15,000 in medical fees plus $3,000-6,000 in medications — totaling $15,000-25,000 per cycle. Many patients require multiple cycles before success. Traditional health insurance plans often exclude IVF or limit coverage to 1-2 cycles; patients may spend $30,000-75,000+ out-of-pocket for a successful pregnancy through IVF. Progyny's smart fertility benefit provides employers' employees with comprehensive IVF coverage through a 'Smart Cycle' model — employees receive a set number of cycle starts, and Progyny manages them through the highest-quality clinics in its network that achieve better success rates than average. Better outcomes mean fewer failed cycles and lower total cost per successful birth, justifying the benefit cost to employers.

AI Prediction SignalNext 5 trading days

Members only

PGNY

+2.8%BUY

ACMR

+1.1%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

Related comparisons

ACMR vs ONTO

Semiconductor Equipment Small Caps

ONEM vs TDOC

Membership Primary Care vs Virtual Care Giant

NVEI vs ACMR

Payment Technology vs Semiconductor Equipment